CD34+ cell mobilization for allogeneic progenitor cell transplantation: efficacy of a short course of G–CSF

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Transfusion

• Publication date

  2001-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1537-2995.2001.41020190.xPMID 11239221
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transplantation of Allogeneic CD 34 + Blood Cells

  2002cited by this paper
• Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience

  1999cited by this paper
• Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF

  1999cited by this paper
• Monitoring of CD34+ cells during leukapheresis allows a single, successful collection of hemopoietic progenitors in patients with low numbers of circulating stem cells

  1999cited by this paper
• Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation

  1998cited by this paper
• Blood and marrow transplantation activity in Europe 1996

  1998cited by this paper
• Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation

  1998cited by this paper
• Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimen.

  1996cited by this paper
• Transplantation of Allogeneic Peripheral Blood Stem Cells Mobilized by Recombinant Human Granulocyte Colony Stimulating Factor

  1996cited by this paper
• Clinical toxicity and laboratory effects of granulocyte‐colony‐ stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures

  1996cited by this paper
• Treatment of normal individuals with granulocyte‐colony‐stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells

  1996cited by this paper
• Allogeneic marrow reconstitution using peripheral blood stem cells: the dawn of a new era

  1996cited by this paper
• Transplantation of allogeneic CD34+ blood cells.

  1996cited by this paper
• THE PLACE OF BLOOD STEM CELLS IN ALLOGENEIC TRANSPLANTATION

  1996cited by this paper
• Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals.

  1996cited by this paper
• G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation of resistant or relapsing acute leukemias.

  1996cited by this paper
• Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation.

  1996cited by this paper
• Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF.

  1996cited by this paper
• Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers.

  1995cited by this paper
• Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor)

  1995cited by this paper
• Peripheral blood stem cells for allografting.

  1995cited by this paper
• Combined transplantation of allogeneic bone marrow and CD34+ blood cells.

  1995cited by this paper
• Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.

  1995cited by this paper
• Peripheral blood stem cells for allografting [editorial] [see comments]

  1995cited by this paper
• Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts.

  1995cited by this paper
• Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor.

  1995cited by this paper
• G‐CSF‐mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft

  1994cited by this paper
• Long‐term safety of treatment with recombinant human granulocyte colony‐stimulating factor (r‐metHuG‐CSF) in patients with severe congenital neutropenias

  1994cited by this paper
• Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation.

  1993cited by this paper
• Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients.

  1991cited by this paper
• Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

  1980cited by this paper
• CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S

  1974cited by this paper

• Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.

  2024cites this paper
• Comparable Outcomes of Allogeneic Peripheral Blood versus Bone Marrow Hematopoietic Stem Cell Transplantation in Major Thalassemia: A Multivariate Long-Term Cohort Analysis.

  2019cites this paper
• Challenge to Predict Mobilized Peripheral Blood Stem Cells on the Fourth Day of Granulocyte Colony-Stimulating Factor Treatment in Healthy Donors: Predictive Value of Basal CD34+ Cell and Platelet Counts.

  2019cites this paper
• Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.

  2014cites this paper
• Safety of hematopoietic stem cell donors

  2012cites this paper
• Cellular therapies supplement: strategies for improving transplant efficiency in the context of cellular therapeutics

  2011cites this paper
• Mobilization kinetics of CD133+ hematoprogenitor cells for hematopoietic grafting

  2009cites this paper
• Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation.

  2009cites this paper
• B-Cell Concentration in the Apheretic Product Predicts Acute Graft-Versus-Host Disease and Treatment-Related Mortality of Allogeneic Peripheral Blood Stem Cell Transplantation

  2008cites this paper
• Effect of the G-CSF schedule for harvesting peripheral blood progenitor cells from healthy donors

  2008cites this paper
• Predictive factors that affect the mobilization of CD34+cells in healthy donors treated with recombinant granulocyte colony‐stimulating factor (G‐CSF)

  2006cites this paper
• Trasplante de progenitores hematopoyéticos

  2006cites this paper
• Use of total leukocyte and platelet counts to guide stem cell apheresis in healthy allogeneic donors treated with G-CSF

  2005cites this paper
• A prospective randomized study on the mobilization of CD34+ cells comparing continuous intravenous vs subcutaneous administration of rhG-CSF in normal donors

  2005cites this paper
• The effect of peptide stimulation on haematopoietic stem cell mobilisation including engraftment characteristics and a note on donor side effects.

  2005cites this paper
• Harvesting peripheral blood progenitor cells from healthy donors with a short course of recombinant human granulocyte‐colony‐stimulating factor

  2005cites this paper
• Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers.

  2005cites this paper
• Renewed granulocyte support practice and its alternatives.

  2004cites this paper
• Factors for PBPC collection efficiency and collection predictors.

  2004cites this paper
• Allogeneic peripheral blood stem cell transplantation for aplastic anaemia: a single centre experience.

  2003cites this paper
• One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.

  2003cites this paper
• Renal transplantation and immunosuppressive therapy do not contraindicate stem-cell donation for bone-marrow transplantation.

  2003cites this paper
• New approaches to hematopoietic cell transplantation in oncology.

  2002cites this paper
• Filgrastim mobilization and collection of allogeneic blood progenitor cells from adult family donors: first interim report of a prospective German multicenter study

  2002cites this paper
• Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors

  2002cites this paper
• Mobilized PBPC concentrates: a maturing blood component

  2001cites this paper